Singapore, Sept. 3 -- Biocytogen Pharmaceuticals (Beijing) has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field.

The licensed VHH antibody molecule was generated from Biocytogen's proprietary RenNano(R) platform. The RenNano(R) platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific...